ABTL-0812 is a Small Molecule owned by Ability Pharmaceuticals, and is involved in 6 clinical trials, of which 3 were completed, 1 is ongoing, and 2 are planned.

ABTL-0812 acts by inhibiting gene expression of AKT, PI3K and mTORC1/C2 pathway which are involved in protein synthesis and cell survival. It also inhibits DNA synthesis by blocking the expression of dihydrofolate reductase (DHFR) needed for cell proliferation. Blocking these two cellular functions leads to the death of tumor cells through autophagy.

The revenue for ABTL-0812 is expected to reach a total of $135m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the ABTL-0812 NPV Report.

ABTL-0812 was originated by Lipopharma and is currently owned by Ability Pharmaceuticals. SciClone Pharmaceuticals Holdings is the other company associated in development or marketing of ABTL-0812.

ABTL-0812 Overview

ABTL-0812 is under development for the treatment of advanced solid tumors including  pancreatic cancer, biliary tract cancer, lung carcinoma, endometrial cancer, non-small cell lung cancer, adult and pediatric neuroblastoma, glioblastoma. It is administered orally. The drug candidate targets AKT, PI3K, dihydrofolate reductase (DHFR) and mTORC1/C2 and is developed based on membrane lipid therapy. It was also under development for the treatment of breast cancer and glioma.

SciClone Pharmaceuticals Holdings Overview

SciClone Pharmaceuticals Holdings (SciClone) develops and commercializes products for the treatment of cancer and immunology. The company’s pipe line products include daya sin, zotye, nomic, angel, ando student, he lesheng, mesna, methotrexate injection, algos and faroda among others. Its under-development products comprise Naxitamab, Circumcising, Vibativ, Vaborem, RRx-001, PEN-866, PT-112, ABTL-0812 and HSP90-PI3K. It also markets Zadaxin (Thymalfasin), an immunostimulatory agent indicated for the treatment of hepatitis as an immune system enhancer. SciClone is headquartered in Hongkong.

The company reported revenues of (Renminbi) CNY2,518.5 million for the fiscal year ended December 2021 (FY2021), an increase of 31.3% over FY2020. In FY2021, the company’s operating margin was 42%, compared to an operating margin of 43.5% in FY2020. In FY2021, the company recorded a net margin of 36.7%, compared to a net margin of 39.3% in FY2020.

Quick View – ABTL-0812

Report Segments
  • Innovator
Drug Name
  • ABTL-0812
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.